# Selexipag

Drug · id `cardio:selexipag` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: UPTRAVI

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

Selexipag, sold as Uptravi, is a prostacyclin receptor agonist. The US label lists treating pulmonary arterial hypertension (PAH, WHO Group I): in adults, to delay disease progression and lower the risk of hospital admission for PAH, and, separately, in pediatric patients aged two years and older, where the label says it reduces NT-proBNP and is expected to delay disease progression and lower the risk of hospital admission for PAH. The label says the medicine acts as an agonist at the prostacyclin receptor and is structurally distinct from prostacyclin.

## Technical summary

RxNorm ingredient 1729002; UNII 5EXC0E384L. MeSH has no descriptor for selexipag (name lookups on 2026-11-18 found only a supplementary concept term), so no MeSH identifier is recorded. RxClass lists the established pharmacologic class Prostacyclin Receptor Agonist, so the record is filed under the prostacyclin pathway page. The label read is the Actelion Pharmaceuticals US, Inc. label for Uptravi, applications NDA207947 and NDA214275, effective 2026-05-28 in openFDA. The adult and pediatric statements sit in separate claims and contexts. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Pediatric patients aged 2 years and older with pulmonary arterial hypertension, as described in the US label of Uptravi

Recipient: Child; Population: Pediatric patients aged two years and older with pulmonary arterial hypertension (PAH, WHO Group I), as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Pediatric patients aged two years and older, as the label states; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label of Uptravi separately lists treating pulmonary arterial hypertension (PAH, WHO Group I) in pediatric patients aged two years and older. The label says Uptravi reduces NT-proBNP and is expected to delay disease progression and lower the risk of hospital admission for PAH.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Child; Population: Pediatric patients aged two years and older with pulmonary arterial hypertension (PAH, WHO Group I), as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Pediatric patients aged two years and older, as the label states; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: The label words the pediatric benefit as expected, and this claim keeps that wording. It is not a finding about how well the medicine works in children. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The adult indication sits in a separate claim.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Uptravi (selexipag tablets and titration pack), Actelion Pharmaceuticals US, Inc. label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id a7a23b87-f892-4e2c-8e2e-ebf841220f90 (manufacturer Actelion Pharmaceuticals US, Inc., application NDA207947 and NDA214275), returned on 2026-11-18. The label text is dated 2026-05-28 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22a7a23b87-f892-4e2c-8e2e-ebf841220f90%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T22:01:39Z. Source state: Current. Version fingerprint: 7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041.
     How it applies: Application number of the label read, NDA207947.
  2. Background: openFDA drug label record for Uptravi (selexipag tablets and titration pack), Actelion Pharmaceuticals US, Inc. label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id a7a23b87-f892-4e2c-8e2e-ebf841220f90 (manufacturer Actelion Pharmaceuticals US, Inc., application NDA207947 and NDA214275), returned on 2026-11-18. The label text is dated 2026-05-28 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22a7a23b87-f892-4e2c-8e2e-ebf841220f90%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T22:01:39Z. Source state: Current. Version fingerprint: 7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041.
     How it applies: Effective date of the label text read, 20260528.
  3. Supports: openFDA drug label record for Uptravi (selexipag tablets and titration pack), Actelion Pharmaceuticals US, Inc. label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id a7a23b87-f892-4e2c-8e2e-ebf841220f90 (manufacturer Actelion Pharmaceuticals US, Inc., application NDA207947 and NDA214275), returned on 2026-11-18. The label text is dated 2026-05-28 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22a7a23b87-f892-4e2c-8e2e-ebf841220f90%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-18T22:01:39Z. Source state: Current. Version fingerprint: 7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041.
     How it applies: Label passage quoted in the research quote table (Q-K30-SEL-LB-06, Q-K30-SEL-LB-07).

## Context: Adults with pulmonary arterial hypertension, as described in the US label of Uptravi

Recipient: Adult; Population: Adults with pulmonary arterial hypertension (PAH, WHO Group I), as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)

### The US label of Uptravi (selexipag, Actelion Pharmaceuticals US, Inc., applications NDA207947 and NDA214275; the version dated 2026-05-28 in openFDA) describes selexipag as a prostacyclin receptor agonist. It lists treating pulmonary arterial hypertension (PAH, WHO Group I) in adults to delay disease progression and lower the risk of hospital admission for PAH.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adults with pulmonary arterial hypertension (PAH, WHO Group I), as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists a pediatric use, which sits in a separate claim.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Uptravi (selexipag tablets and titration pack), Actelion Pharmaceuticals US, Inc. label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id a7a23b87-f892-4e2c-8e2e-ebf841220f90 (manufacturer Actelion Pharmaceuticals US, Inc., application NDA207947 and NDA214275), returned on 2026-11-18. The label text is dated 2026-05-28 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22a7a23b87-f892-4e2c-8e2e-ebf841220f90%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T22:01:39Z. Source state: Current. Version fingerprint: 7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041.
     How it applies: Application number of the label read, NDA207947.
  2. Background: openFDA drug label record for Uptravi (selexipag tablets and titration pack), Actelion Pharmaceuticals US, Inc. label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id a7a23b87-f892-4e2c-8e2e-ebf841220f90 (manufacturer Actelion Pharmaceuticals US, Inc., application NDA207947 and NDA214275), returned on 2026-11-18. The label text is dated 2026-05-28 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22a7a23b87-f892-4e2c-8e2e-ebf841220f90%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T22:01:39Z. Source state: Current. Version fingerprint: 7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041.
     How it applies: Effective date of the label text read, 20260528.
  3. Supports: openFDA drug label record for Uptravi (selexipag tablets and titration pack), Actelion Pharmaceuticals US, Inc. label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id a7a23b87-f892-4e2c-8e2e-ebf841220f90 (manufacturer Actelion Pharmaceuticals US, Inc., application NDA207947 and NDA214275), returned on 2026-11-18. The label text is dated 2026-05-28 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22a7a23b87-f892-4e2c-8e2e-ebf841220f90%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-18T22:01:39Z. Source state: Current. Version fingerprint: 7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041.
     How it applies: Label passage quoted in the research quote table (Q-K30-SEL-LB-04, Q-K30-SEL-LB-05).

## Connected pages

- Selexipag is a prostacyclin receptor agonist (FDA established pharmacologic class in RxClass): Prostacyclin pathway drugs (`cardio:prostacyclin-pathway-drugs`)
- FDA label lists pulmonary arterial hypertension (WHO Group I) in adults, to delay disease progression and lower the risk of hospital admission for PAH, as an indication: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-uptravi-label-indications` and its context]
- FDA label separately lists pulmonary arterial hypertension in pediatric patients aged two years and older as an indication: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-uptravi-label-paediatric` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: 540800dee242798c7b82bf40066d44f36c89bcab18746ed3e9dcdeaee5ae1385
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
